Evidence map›Paper›PMID 31889993›Full record

ArticleInfectious agents and cancer2019

Combination of the gamma-glutamyltransferase-to-prealbumin ratio and other indicators may be a novel marker for predicting the prognosis of patients with hepatocellular carcinoma undergoing locoregional ablative therapies.

Q Wang, P Zhao, N He, J P Sun, K Li, C R Zang, Y N Zhao, Y Zhao, Y H Zhang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Infectious agents and cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Q Wang1Research center for biomedical resources, Beijing You'an Hospital, Capital Medical University, Beijing, 100069 China.ORCID 0000-0003-0461-1469
P Zhao2Interventional therapy center for oncology, Beijing You'an Hospital, Capital Medical University, Beijing, 100069 China.
N He2Interventional therapy center for oncology, Beijing You'an Hospital, Capital Medical University, Beijing, 100069 China.
J P Sun1Research center for biomedical resources, Beijing You'an Hospital, Capital Medical University, Beijing, 100069 China.
K Li1Research center for biomedical resources, Beijing You'an Hospital, Capital Medical University, Beijing, 100069 China.
C R Zang1Research center for biomedical resources, Beijing You'an Hospital, Capital Medical University, Beijing, 100069 China.
Y N Zhao1Research center for biomedical resources, Beijing You'an Hospital, Capital Medical University, Beijing, 100069 China.
Y Zhao *3Clinical detection center, Beijing You'an Hospital, Capital Medical University, 8 Xitoutiao, Youanmenwai Street, Fengtai District, Beijing, 100069 China.
Y H Zhang *1Research center for biomedical resources, Beijing You'an Hospital, Capital Medical University, Beijing, 100069 China.
Capital Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe aim of this study was to investigate the prognostic significance of the serum γ-glutamyltransferase (γ-GT)-to-prealbumin ratio (GPR) and whether combining this ratio with other parameters can lead to an improved prognostic value for patients with hepatocellular carcinoma (HCC) undergoing transcatheter arterial chemoembolization (TACE) combined with local ablation therapy.

methodsA total of 235 HCC patients who were treated with combined therapies were retrospectively analyzed. The demographic data and clinicopathological data were collected. A fibrinogen (Fib)-GPR score of 2 was assigned to patients with elevated Fib and GPR values, and a score of 1 or 0 was assigned to patients with one or neither of these two markers, respectively. In addition, an N-score of 2 was assigned to patients with low neutrophil and high GPR values, and a score of 1 or 0 was assigned to patients with one or neither of these two markers, respectively. The optimal cutoff values and prognostic roles of GPR and other markers were identified according to the time-dependent receiver operating characteristic (ROC) curves and Youden's index.

resultsMultiple tumors, high levels of α-fetoprotein (AFP) and Fib, as well as a high GPR, were found to be independent risk factors in recurrent patients, while multiple tumors, a low neutrophil count, and a high GPR were associated with reduced overall survival (OS) in patients with HCC who received combined therapies. Patients with a Fib-GPR score of 2 and N-GPR score of 2 had poor recurrence-free survival (RFS) and OS, respectively.

conclusionsFib-GPR and N-GPR scores may be helpful in predicting both recurrence and the prognosis of HCC patients, thereby assisting in the process to make a true clinical decision and optimize therapeutic options.

Indexed as

Gamma-glutamyltransferaseHepatocellular carcinomaLocoregional ablationPrealbuminPrognosisTranscatheter arterial chemoembolization

Identifiers

PMID31889993
PMCPMC6921576
OpenAlexW2996592792

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.